Please login to the form below
leukaemia
This page shows the latest leukaemia news and features for those working in and with pharma, biotech and healthcare.
Amgen’s Riabni combination granted FDA approval for rheumatoid arthritis
Amgen’s treatment has already been approved for use in adult patients with non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukaemia (CLL), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). ... Riabni is not currently
Latest news
-
EC approves Novartis’ Kymriah for advanced blood cancer
In addition to refractory follicular lymphoma, Kymriah is also approved to treat paediatric and young adults up to and including 25 years of age with B cell acute lymphoblastic leukaemia (ALL)
-
FDA lifts hold on Gilead’s clinical trials for leukaemia
As a consequence, enrolment in the US can resume for the studies into the therapies, which treat both myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). ... One in three people with the condition will progress to AML, making it one of the
-
FDA places partial clinical hold on three Gilead phase 3 trials for MDS and AML treatments
for patients with myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) and AML patients unable to receive intensive chemotherapy.
-
BMS and Century Therapeutics agree on deal potentially worth over $3bn
The first two programmes involve an acute myeloid leukaemia programme coupled with a programme in multiple myeloma.
-
FDA approves first drug to prevent graft-versus-host disease
Bone marrow transplants for the treatment of leukaemia and other blood cancers have a long history, with the first procedure in 1957 in identical twins leading its pioneer, Dr E Donnall
More from news
Approximately 76 fully matching, plus 434 partially matching documents found.
Latest Intelligence
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
The product underwent its first phase 1 trial test in January 2020 with a patient who was suffering from acute myeloid leukaemia.
-
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
symptoms including bladder/ bowel dysfunction, high blood pressure and leukaemia, and can reduce life expectancy by up to 15 years.
-
Cortellis Drugs to Watch in 2020 report
3. Novartis’ OMB-157 is a monthly or 12-weekly subcutaneous formulation of the anti-CD20 monoclonal antibody Arzerra (which is indicated as an intravenous infusion for chronic lymphocytic leukaemia) in
-
20 for 2020 – Five pharma companies to watch
DS-8201 is central to that effort, but it’s also hoping for strong support from other pipeline drugs like quizartinib for relapsed or refractory FLT3-positive acute myeloid leukaemia (AML) –
-
2019: CRISPR and therapeutic gene editing comes of age
An 11-month old baby suffering from CD19-positive acute lymphoblastic leukaemia (ALL) was treated with modified donor T cells that had been engineered to attack leukaemia cells.
More from intelligence
Approximately 1 fully matching, plus 49 partially matching documents found.
Latest appointments
-
Storm Therapeutics bolsters its team
As a clinician-scientist at the University of Melbourne, Professor Dawson has experience in epigenetics having spent several years researching epigenetic regulation of leukaemia stem cells.
-
Helen Parfitt joins Research Partnership
She will also focus on the firm’s recently expanded oncology portfolio, which has added squamous cell carcinoma of the head and neck (SCCHN) and chronic myeloid leukaemia (CML) to its
-
Actinium appoints director of clinical operations
Bergonio moves from Novartis, where he served as an expert clinical manager in the Swiss firm's oncology global development unit, specialising in acute myeloid leukaemia.
-
Astellas bolsters oncology clinical development leadership
breast cancer, leukaemia, lung cancer and prostate cancer.
-
Akinion appoints Dr Richard Jones as CEO
In his new role at Akinion Pharmaceuticals Dr Jones will oversee a company focused on acute myeloid leukaemia and its lead candidate drug AKN-028, a small molecule kinase inhibitor currently
More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest from PMHub
-
Why you should feel optimistic about the future of healthcare
Precision medicines already exist; imatinib works to treat leukaemia only when the cancer cells have a particular genetic makeup, Sotorasib targets a specific mutation in people with lung cancer to halt
-
Frontera wins at IPA Best of Health 2016
For the Pip award, which aimed to promote the work of the Elimination of Leukaemia Fund (ELF) Mind and Body Service, Frontera was awarded for the ‘White Cell’.
-
Understanding the evolving CAR-T market
The therapy was trialled in paediatric and young adult lymphoblastic leukaemia patients suffering from the most aggressive forms of the disease.
-
Spotlight interview: 15 minutes on patient-centricity in pharma
We have recently developed an above-brand app called “CML Life” which is for patients with chronic myeloid leukaemia.
-
Precision paediatrics: Treating patients with CAR-T
There are a number of trials being undertaken throughout the world, but the first licensed product, Novartis’ Kymriah, is now available for the treatment of leukaemia and is live at GOSH.
More from PMHub
Approximately 2 fully matching, plus 15 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Biogen and Happify Health team up to create digital platform for MS patients
- Moderna to launch Innovation and Technology Center in the UK
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Why project managers are key to creating quality content
- Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis
- How Resonant’s innovation and creativity resolve healthcare communications challenges
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- A creative awakening – how pharma is bringing innovation to the patient journey
- AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Novartis endorses Kigali Declaration by investing $250m for tropical diseases
- Pfizer, Mylan move ahead with generics merger and spin-out
PMHub
Viseven
Viseven is a Global MarTech Services Provider for Pharma and Life Sciences Industries...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
